Buy Rocket pharma now?

**Rocket Pharmaceuticals (RCKT) presents a complex investment scenario**, and here's why:

1. **Financial Metrics**: The stock has a negative P/E ratio of -7.01, which is not indicative of a healthy company. The high Price-to-Book (P/B) ratio of 4.54 suggests that the market may be expecting significant future growth to justify the valuation. However, the absence of positive operating revenues and a significant accumulated deficit raise concerns about the company's financial sustainability.

2. **Pipeline and Future Prospects**: Rocket Pharmaceuticals has two gene therapy candidates anticipating near-term review, which could be potential catalysts for future growth. The appointment of Mikael Dolsten to the board, with his extensive experience in pharmaceutical management, is a positive sign for the company's scientific capabilities.
3. **Market Sentiment and Performance**: The stock has experienced a significant drop from its previous trading price, which could indicate market skepticism about the company's financials or the timeline for its pipeline products. The recent negative trend in share performance could be a concern for investors.
4. **Operational Outlook**: The company's operational runway is expected to support it into 2026, but the rate of cash burn and the need for future capital raises questions about the company's ability to sustain operations without external financing.

In conclusion, while Rocket Pharmaceuticals has potential based on its pipeline, the current financial metrics and market performance raise concerns. Investors should carefully consider the company's operational outlook, the timing and success of its pipeline products, and the associated risks before making an investment decision.